Calvin Lyons, MD
Colon & Rectal Surgery · Las Vegas, NVNPI 1811149404
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (40.3%), education and consulting fees — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Intuitive Surgical at 33.6% of the total. Reporting peaked in 2023 at $2,125 and has fallen 68.7% since, to $665 in 2025.
Across 77 payments — averaging $78.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- Medtronic$665
- Braintree Laboratories, Inc.$410
- Covidien LP$325
- Merck$318
- Takeda Pharmaceuticals U.S.A., Inc.$305
- plus $2K from 30 others
What the payments were for
- Consulting fees$97516%
- Speaking & faculty fees$2755%
- Travel & lodging$83814%
- Food & beverage$2,43840%
- Education$1,00017%
- Gifts$3686%
- Other$1593%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $2,035 |
| Medtronic | 2 | $665 |
| Braintree Laboratories, Inc. | 12 | $410 |
| Covidien LP | 1 | $325 |
| Merck | 8 | $318 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $305 |
| AbbVie | 2 | $244 |
| GSK | 2 | $201 |
| Acera Surgical, Inc. | 2 | $193 |
| Foundation Medicine, Inc. | 1 | $148 |
| Smith+Nephew | 1 | $131 |
| Lundbeck LLC | 1 | $120 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $99 |
| Welch Allyn | 1 | $80 |
| Baxter Healthcare | 1 | $80 |
| Dendreon Pharmaceuticals LLC | 3 | $72 |
| Coloplast | 2 | $60 |
| Pacira Pharmaceuticals Incorporated | 2 | $50 |
| Johnson & Johnson | 2 | $49 |
| Conmed Corporation | 1 | $44 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
| Calyxo, Inc. | 1 | $35 |
| La Jolla Pharmaceutical Company | 1 | $34 |
| Ferring Pharmaceuticals Inc. | 2 | $34 |
| Sanara Medtech Inc. | 1 | $31 |
| Vioptix Inc | 1 | $30 |
| Antares Pharma, Inc. | 2 | $30 |
| Innovation Technologies Inc | 1 | $27 |
| KCI USA, Inc. | 1 | $26 |
| Endo USA, Inc. | 1 | $25 |
| Urogen Pharma, Inc. | 1 | $24 |
| Novartis | 1 | $23 |
| Teleflex LLC | 1 | $22 |
| 180 Medical, Inc. | 1 | $21 |
| Olympus America Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$1,000
- Da Vinci Surgical System$819
- GATTEX$275
- Skyrizi$244
- Restrata Wound Matrix$166
- FOUNDATIONONE$148
- FOUNDATIONONE HEME$148
- FOUNDATIONONE CDX$148
- FOUNDATIONFOCUS$148
- FOUNDATIONONE LIQUID CDX$148
- GRAFIX PL$131
- Oasis$131
- BEXSERO$119
- BRIDION$113
- ENTEREG$102
How this compares
Too few colon & rectal surgery providers in Nevadato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SutabSod Sulf/Pot Chloride/Mag Sulf | 11 | $1,773 |
| Neomycin Sulfate | 14 | $97 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $92 |
| Metronidazole | 13 | $32 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Braintree Laboratories, Inc.Sutab | $410 | $1,77311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few colon & rectal surgery providers in Nevadaon file to place this against a meaningful peer group, so we don't.
Other colon & rectal surgery in Las Vegas
- Garrett FriedmanLas Vegas$1.2M
- Roger HsiungLas Vegas$44K
- Ren Yu ZhangLas Vegas$8K
- Ketan ThankiLas Vegas$7K
- Melissa MilesLas Vegas$5K
- Joseph ThorntonLas Vegas$5K
- Lance HornerLas Vegas$5K
- Katherine SpechtLas Vegas$4K
- Stephanie WishnevLas Vegas$829
- Kent SasseReno$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.